RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jose L. Lopez-Ribot to Candida albicans

Back to Details
This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about Candida albicans.
Jose L. Lopez-Ribot
Connection Strength
20.731
Candida albicans
  1. Ajetunmobi OH, Chaturvedi AK, Badali H, Vaccaro A, Najvar L, Wormley FL, Wiederhold NP, Patterson TF, Lopez-Ribot JL. Screening the medicine for malaria venture's Pandemic Response Box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation. APMIS. 2023 Nov; 131(11):613-625.
    View in: PubMed
    Score: 0.817
  2. Romo JA, Zhang H, Cai H, Kadosh D, Koehler JR, Saville SP, Wang Y, Lopez-Ribot JL. Global Transcriptomic Analysis of the Candida albicans Response to Treatment with a Novel Inhibitor of Filamentation. mSphere. 2019 09 11; 4(5).
    View in: PubMed
    Score: 0.629
  3. Montelongo-Jauregui D, Saville SP, Lopez-Ribot JL. Contributions of Candida albicans Dimorphism, Adhesive Interactions, and Extracellular Matrix to the Formation of Dual-Species Biofilms with Streptococcus gordonii. mBio. 2019 06 18; 10(3).
    View in: PubMed
    Score: 0.619
  4. Romo JA, Pierce CG, Esqueda M, Hung CY, Saville SP, Lopez-Ribot JL. In Vitro Characterization of a Biaryl Amide Anti-virulence Compound Targeting Candida albicans Filamentation and Biofilm Formation. Front Cell Infect Microbiol. 2018; 8:227.
    View in: PubMed
    Score: 0.580
  5. Romo JA, Pierce CG, Chaturvedi AK, Lazzell AL, McHardy SF, Saville SP, Lopez-Ribot JL. Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of Candida albicans Filamentation. mBio. 2017 Dec 05; 8(6).
    View in: PubMed
    Score: 0.557
  6. Vila T, Lopez-Ribot JL. Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors. Antimicrob Agents Chemother. 2017 01; 61(1).
    View in: PubMed
    Score: 0.521
  7. Vila T, Romo JA, Pierce CG, McHardy SF, Saville SP, Lopez-Ribot JL. Targeting Candida albicans filamentation for antifungal drug development. Virulence. 2017 02 17; 8(2):150-158.
    View in: PubMed
    Score: 0.502
  8. Wiederhold NP, Patterson TF, Srinivasan A, Chaturvedi AK, Fothergill AW, Wormley FL, Ramasubramanian AK, Lopez-Ribot JL. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. Virulence. 2017 02 17; 8(2):138-142.
    View in: PubMed
    Score: 0.502
  9. Vila TV, Chaturvedi AK, Rozental S, Lopez-Ribot JL. In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. Antimicrob Agents Chemother. 2015 Dec; 59(12):7611-20.
    View in: PubMed
    Score: 0.478
  10. Pierce CG, Saville SP, Lopez-Ribot JL. High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation. Pathog Dis. 2014 Apr; 70(3):423-31.
    View in: PubMed
    Score: 0.430
  11. Kadosh D, Lopez-Ribot JL. Candida albicans: adapting to succeed. Cell Host Microbe. 2013 Nov 13; 14(5):483-5.
    View in: PubMed
    Score: 0.420
  12. Pierce CG, Lopez-Ribot JL. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov. 2013 Sep; 8(9):1117-26.
    View in: PubMed
    Score: 0.407
  13. Uppuluri P, Chaturvedi AK, Jani N, Pukkila-Worley R, Monteagudo C, Mylonakis E, K?hler JR, Lopez Ribot JL. Physiologic expression of the Candida albicans pescadillo homolog is required for virulence in a murine model of hematogenously disseminated candidiasis. Eukaryot Cell. 2012 Dec; 11(12):1552-6.
    View in: PubMed
    Score: 0.391
  14. Chaturvedi AK, Lazzell AL, Saville SP, Wormley FL, Monteagudo C, Lopez-Ribot JL. Validation of the tetracycline regulatable gene expression system for the study of the pathogenesis of infectious disease. PLoS One. 2011; 6(5):e20449.
    View in: PubMed
    Score: 0.354
  15. Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother. 2011 Jul; 55(7):3591-3.
    View in: PubMed
    Score: 0.352
  16. Uppuluri P, Lopez-Ribot JL. An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. Virulence. 2010 Nov-Dec; 1(6):483-7.
    View in: PubMed
    Score: 0.340
  17. Pierce CG, Uppuluri P, Tummala S, Lopez-Ribot JL. A 96 well microtiter plate-based method for monitoring formation and antifungal susceptibility testing of Candida albicans biofilms. J Vis Exp. 2010 Oct 21; (44).
    View in: PubMed
    Score: 0.340
  18. Uppuluri P, Pierce CG, Thomas DP, Bubeck SS, Saville SP, Lopez-Ribot JL. The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryot Cell. 2010 Oct; 9(10):1531-7.
    View in: PubMed
    Score: 0.335
  19. Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, K?hler JR, Kadosh D, Lopez-Ribot JL. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 2010 Mar 26; 6(3):e1000828.
    View in: PubMed
    Score: 0.326
  20. Uppuluri P, Pierce CG, L?pez-Ribot JL. Candida albicans biofilm formation and its clinical consequences. Future Microbiol. 2009 Dec; 4(10):1235-7.
    View in: PubMed
    Score: 0.319
  21. Uppuluri P, Dinakaran H, Thomas DP, Chaturvedi AK, Lopez-Ribot JL. Characteristics of Candida albicans biofilms grown in a synthetic urine medium. J Clin Microbiol. 2009 Dec; 47(12):4078-83.
    View in: PubMed
    Score: 0.316
  22. Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother. 2009 Sep; 64(3):567-70.
    View in: PubMed
    Score: 0.311
  23. Redding S, Bhatt B, Rawls HR, Siegel G, Scott K, Lopez-Ribot J. Inhibition of Candida albicans biofilm formation on denture material. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 May; 107(5):669-72.
    View in: PubMed
    Score: 0.307
  24. Uppuluri P, Chaturvedi AK, Lopez-Ribot JL. Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia. 2009 Sep; 168(3):101-9.
    View in: PubMed
    Score: 0.306
  25. Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis. Clin Vaccine Immunol. 2009 Mar; 16(3):430-2.
    View in: PubMed
    Score: 0.301
  26. Pierce CG, Thomas DP, L?pez-Ribot JL. Effect of tunicamycin on Candida albicans biofilm formation and maintenance. J Antimicrob Chemother. 2009 Mar; 63(3):473-9.
    View in: PubMed
    Score: 0.299
  27. Lee SA, Jones J, Hardison S, Kot J, Khalique Z, Bernardo SM, Lazzell A, Monteagudo C, Lopez-Ribot J. Candida albicans VPS4 is required for secretion of aspartyl proteases and in vivo virulence. Mycopathologia. 2009 Feb; 167(2):55-63.
    View in: PubMed
    Score: 0.294
  28. Ramage G, Wickes BL, L?pez-Ribot JL. A seed and feed model for the formation of Candida albicans biofilms under flow conditions using an improved modified Robbins device. Rev Iberoam Micol. 2008 Mar; 25(1):37-40.
    View in: PubMed
    Score: 0.283
  29. Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect Immun. 2008 Jan; 76(1):97-102.
    View in: PubMed
    Score: 0.276
  30. Ramage G, Wickes BL, L?pez-Ribot JL. Inhibition on Candida albicans biofilm formation using divalent cation chelators (EDTA). Mycopathologia. 2007 Dec; 164(6):301-6.
    View in: PubMed
    Score: 0.275
  31. Thomas DP, Pitarch A, Monteoliva L, Gil C, Lopez-Ribot JL. Proteomics to study Candida albicans biology and pathogenicity. Infect Disord Drug Targets. 2006 Dec; 6(4):335-41.
    View in: PubMed
    Score: 0.259
  32. Thomas DP, Bachmann SP, Lopez-Ribot JL. Proteomics for the analysis of the Candida albicans biofilm lifestyle. Proteomics. 2006 Nov; 6(21):5795-804.
    View in: PubMed
    Score: 0.258
  33. Thomas DP, Viudes A, Monteagudo C, Lazzell AL, Saville SP, L?pez-Ribot JL. A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis. Proteomics. 2006 Nov; 6(22):6033-41.
    View in: PubMed
    Score: 0.258
  34. Saville SP, Thomas DP, L?pez Ribot JL. A role for Efg1p in Candida albicans interactions with extracellular matrices. FEMS Microbiol Lett. 2006 Mar; 256(1):151-8.
    View in: PubMed
    Score: 0.246
  35. L?pez-Ribot JL. Candida albicans biofilms: more than filamentation. Curr Biol. 2005 Jun 21; 15(12):R453-5.
    View in: PubMed
    Score: 0.235
  36. Ramage G, L?pez-Ribot JL. Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol Med. 2005; 118:71-9.
    View in: PubMed
    Score: 0.227
  37. L?pez-Ribot JL, Casanova M, Murgui A, Mart?nez JP. Antibody response to Candida albicans cell wall antigens. FEMS Immunol Med Microbiol. 2004 Jul 01; 41(3):187-96.
    View in: PubMed
    Score: 0.219
  38. Monteagudo C, Viudes A, Lazzell A, Martinez JP, Lopez-Ribot JL. Tissue invasiveness and non-acidic pH in human candidiasis correlate with "in vivo" expression by Candida albicans of the carbohydrate epitope recognised by new monoclonal antibody 1H4. J Clin Pathol. 2004 Jun; 57(6):598-603.
    View in: PubMed
    Score: 0.218
  39. Viudes A, Lazzell A, Perea S, Kirkpatrick WR, Peman J, Patterson TF, Martinez JP, L?pez-Ribot JL. The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis. FEMS Microbiol Lett. 2004 Mar 19; 232(2):133-8.
    View in: PubMed
    Score: 0.215
  40. Li X, Brown N, Chau AS, L?pez-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004 Jan; 53(1):74-80.
    View in: PubMed
    Score: 0.211
  41. Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, L?pez-Ribot JL. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother. 2003 Nov; 47(11):3657-9.
    View in: PubMed
    Score: 0.210
  42. Saville SP, Lazzell AL, Monteagudo C, Lopez-Ribot JL. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell. 2003 Oct; 2(5):1053-60.
    View in: PubMed
    Score: 0.208
  43. Ramage G, Borghi E, Rodrigues CF, Kean R, Williams C, Lopez-Ribot J. Our current clinical understanding of Candida biofilms: where are we two decades on? APMIS. 2023 Nov; 131(11):636-653.
    View in: PubMed
    Score: 0.201
  44. Ajetunmobi OH, Wall G, Bonifacio BV, Montelongo-Jauregui D, Lopez-Ribot JL. A 384-Well Microtiter Plate Model for Candida Biofilm Formation and Its Application to High-Throughput Screening. Methods Mol Biol. 2023; 2658:53-64.
    View in: PubMed
    Score: 0.198
  45. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, L?pez-Ribot JL. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2002 Nov; 46(11):3591-6.
    View in: PubMed
    Score: 0.195
  46. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, L?pez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother. 2002 Nov; 46(11):3634-6.
    View in: PubMed
    Score: 0.195
  47. Ramage G, Saville SP, Wickes BL, L?pez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol. 2002 Nov; 68(11):5459-63.
    View in: PubMed
    Score: 0.195
  48. Bachmann SP, Patterson TF, L?pez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002 Jun; 40(6):2228-30.
    View in: PubMed
    Score: 0.190
  49. Ramage G, Bachmann S, Patterson TF, Wickes BL, L?pez-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother. 2002 Jun; 49(6):973-80.
    View in: PubMed
    Score: 0.190
  50. Ramage G, Vande Walle K, Wickes BL, L?pez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 2001 Sep; 45(9):2475-9.
    View in: PubMed
    Score: 0.180
  51. Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab. 2001 Aug; 20(7):42-4.
    View in: PubMed
    Score: 0.179
  52. Viudes A, Perea S, Lopez-Ribot JL. Identification of continuous B-cell epitopes on the protein moiety of the 58-kiloDalton cell wall mannoprotein of Candida albicans belonging to a family of immunodominant fungal antigens. Infect Immun. 2001 May; 69(5):2909-19.
    View in: PubMed
    Score: 0.176
  53. Vazquez-Mu?oz R, Arellano-Jimenez MJ, Lopez FD, Lopez-Ribot JL. Protocol optimization for a fast, simple and economical chemical reduction synthesis of antimicrobial silver nanoparticles in non-specialized facilities. BMC Res Notes. 2019 Nov 27; 12(1):773.
    View in: PubMed
    Score: 0.160
  54. Lopez-Ribot JL, McAtee RK, Kirkpatrick WR, La Valle R, Patterson TF. Low levels of antigenic variability in fluconazole-susceptible and -resistant Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Clin Diagn Lab Immunol. 1999 Sep; 6(5):665-70.
    View in: PubMed
    Score: 0.157
  55. Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1999 Jul; 43(7):1621-30.
    View in: PubMed
    Score: 0.155
  56. Wall G, Montelongo-Jauregui D, Vidal Bonifacio B, Lopez-Ribot JL, Uppuluri P. Candida albicans biofilm growth and dispersal: contributions to pathogenesis. Curr Opin Microbiol. 2019 12; 52:1-6.
    View in: PubMed
    Score: 0.154
  57. Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson TF. Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 1998 Nov; 42(11):2932-7.
    View in: PubMed
    Score: 0.148
  58. Liu NN, Uppuluri P, Broggi A, Besold A, Ryman K, Kambara H, Solis N, Lorenz V, Qi W, Acosta-Zald?var M, Emami SN, Bao B, An D, Bonilla FA, Sola-Visner M, Filler SG, Luo HR, Engstr?m Y, Ljungdahl PO, Culotta VC, Zanoni I, Lopez-Ribot JL, K?hler JR. Intersection of phosphate transport, oxidative stress and TOR signalling in Candida albicans virulence. PLoS Pathog. 2018 07; 14(7):e1007076.
    View in: PubMed
    Score: 0.146
  59. Lara HH, Guisbiers G, Mendoza J, Mimun LC, Vincent BA, Lopez-Ribot JL, Nash KL. Synergistic antifungal effect of chitosan-stabilized selenium nanoparticles synthesized by pulsed laser ablation in liquids against Candida albicans biofilms. Int J Nanomedicine. 2018; 13:2697-2708.
    View in: PubMed
    Score: 0.143
  60. Cleary IA, Reinhard SM, Lazzell AL, Monteagudo C, Thomas DP, Lopez-Ribot JL, Saville SP. Examination of the pathogenic potential of Candida albicans filamentous cells in an animal model of haematogenously disseminated candidiasis. FEMS Yeast Res. 2016 Mar; 16(2):fow011.
    View in: PubMed
    Score: 0.123
  61. Lara HH, Romero-Urbina DG, Pierce C, Lopez-Ribot JL, Arellano-Jim?nez MJ, Jose-Yacaman M. Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study. J Nanobiotechnology. 2015 Dec 15; 13:91.
    View in: PubMed
    Score: 0.121
  62. Lopez-Ribot JL, Cortlandt DA, Straus DC, Morrow KJ, Chaffin WL. Complex interaction between different proteinaceous components within the cell-wall structure of Candida albicans. Mycopathologia. 1995 Nov; 132(2):87-93.
    View in: PubMed
    Score: 0.120
  63. Albataineh MT, Lazzell A, Lopez-Ribot JL, Kadosh D. Ppg1, a PP2A-type protein phosphatase, controls filament extension and virulence in Candida albicans. Eukaryot Cell. 2014 Dec; 13(12):1538-47.
    View in: PubMed
    Score: 0.112
  64. Sarkar S, Uppuluri P, Pierce CG, Lopez-Ribot JL. In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother. 2014; 58(2):1183-6.
    View in: PubMed
    Score: 0.105
  65. Srinivasan A, Gupta CM, Agrawal CM, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. Drug susceptibility of matrix-encapsulated Candida albicans nano-biofilms. Biotechnol Bioeng. 2014 Feb; 111(2):418-24.
    View in: PubMed
    Score: 0.104
  66. Srinivasan A, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. High-throughput nano-biofilm microarray for antifungal drug discovery. mBio. 2013 Jun 25; 4(4).
    View in: PubMed
    Score: 0.102
  67. Siles SA, Srinivasan A, Pierce CG, Lopez-Ribot JL, Ramasubramanian AK. High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother. 2013 Aug; 57(8):3681-7.
    View in: PubMed
    Score: 0.102
  68. Banerjee M, Uppuluri P, Zhao XR, Carlisle PL, Vipulanandan G, Villar CC, L?pez-Ribot JL, Kadosh D. Expression of UME6, a key regulator of Candida albicans hyphal development, enhances biofilm formation via Hgc1- and Sun41-dependent mechanisms. Eukaryot Cell. 2013 Feb; 12(2):224-32.
    View in: PubMed
    Score: 0.098
  69. Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening. J Vis Exp. 2012 Jul 18; (65):e3845.
    View in: PubMed
    Score: 0.096
  70. Martins M, Lazzell AL, Lopez-Ribot JL, Henriques M, Oliveira R. Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. J Basic Microbiol. 2012 Aug; 52(4):487-91.
    View in: PubMed
    Score: 0.091
  71. Dahlan AA, Haveman CW, Ramage G, Lopez-Ribot JL, Redding SW. Sodium hypochlorite, chlorhexidine gluconate, and commercial denture cleansers as disinfecting agents against Candida albicans: An in vitro comparison study. Gen Dent. 2011 Nov-Dec; 59(6):e224-9.
    View in: PubMed
    Score: 0.091
  72. Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, Lopez-Ribot JL, Andes D, Cowen LE. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 2011 Sep; 7(9):e1002257.
    View in: PubMed
    Score: 0.090
  73. Lopez-Ribot JL, Casanova M, Martinez JP, Sentandreu R. Characterization of cell wall proteins of yeast and hydrophobic mycelial cells of Candida albicans. Infect Immun. 1991 Jul; 59(7):2324-32.
    View in: PubMed
    Score: 0.089
  74. Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses. 2012 Jan; 55(1):80-5.
    View in: PubMed
    Score: 0.089
  75. Srinivasan A, Uppuluri P, Lopez-Ribot J, Ramasubramanian AK. Development of a high-throughput Candida albicans biofilm chip. PLoS One. 2011 Apr 22; 6(4):e19036.
    View in: PubMed
    Score: 0.088
  76. Martins M, Uppuluri P, Thomas DP, Cleary IA, Henriques M, Lopez-Ribot JL, Oliveira R. Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia. 2010 May; 169(5):323-31.
    View in: PubMed
    Score: 0.080
  77. Thomas DP, Lopez-Ribot JL, Lee SA. A proteomic analysis of secretory proteins of a pre-vacuolar mutant of Candida albicans. J Proteomics. 2009 Dec 01; 73(2):342-51.
    View in: PubMed
    Score: 0.079
  78. Grubb SE, Murdoch C, Sudbery PE, Saville SP, Lopez-Ribot JL, Thornhill MH. Adhesion of Candida albicans to endothelial cells under physiological conditions of flow. Infect Immun. 2009 Sep; 77(9):3872-8.
    View in: PubMed
    Score: 0.078
  79. Carlisle PL, Banerjee M, Lazzell A, Monteagudo C, L?pez-Ribot JL, Kadosh D. Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):599-604.
    View in: PubMed
    Score: 0.075
  80. Grubb SE, Murdoch C, Sudbery PE, Saville SP, Lopez-Ribot JL, Thornhill MH. Candida albicans-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis. Infect Immun. 2008 Oct; 76(10):4370-7.
    View in: PubMed
    Score: 0.072
  81. Banerjee M, Thompson DS, Lazzell A, Carlisle PL, Pierce C, Monteagudo C, L?pez-Ribot JL, Kadosh D. UME6, a novel filament-specific regulator of Candida albicans hyphal extension and virulence. Mol Biol Cell. 2008 Apr; 19(4):1354-65.
    View in: PubMed
    Score: 0.070
  82. P?rez A, Pedr?s B, Murgui A, Casanova M, L?pez-Ribot JL, Mart?nez JP. Biofilm formation by Candida albicans mutants for genes coding fungal proteins exhibiting the eight-cysteine-containing CFEM domain. FEMS Yeast Res. 2006 Nov; 6(7):1074-84.
    View in: PubMed
    Score: 0.064
  83. Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL, Milne GT. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother. 2006 Oct; 50(10):3312-6.
    View in: PubMed
    Score: 0.064
  84. Ramage G, Tomsett K, Wickes BL, L?pez-Ribot JL, Redding SW. Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jul; 98(1):53-9.
    View in: PubMed
    Score: 0.055
  85. Ullmann BD, Myers H, Chiranand W, Lazzell AL, Zhao Q, Vega LA, Lopez-Ribot JL, Gardner PR, Gustin MC. Inducible defense mechanism against nitric oxide in Candida albicans. Eukaryot Cell. 2004 Jun; 3(3):715-23.
    View in: PubMed
    Score: 0.055
  86. Hernandez S, L?pez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004 Apr; 48(4):1382-3.
    View in: PubMed
    Score: 0.054
  87. Martinez M, L?pez-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol. 2002 Sep; 40(9):3135-9.
    View in: PubMed
    Score: 0.048
  88. Ramage G, VandeWalle K, L?pez-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett. 2002 Aug 27; 214(1):95-100.
    View in: PubMed
    Score: 0.048
  89. Mart?nez M, L?pez-Ribot JL, Kirkpatrick WR, Bachmann SP, Perea S, Ruesga MT, Patterson TF. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother. 2002 Mar; 49(3):515-24.
    View in: PubMed
    Score: 0.047
  90. Perea S, L?pez-Ribot JL, Kirkpatrick WR, McAtee RK, Santill?n RA, Mart?nez M, Calabrese D, Sanglard D, Patterson TF. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001 Oct; 45(10):2676-84.
    View in: PubMed
    Score: 0.045
  91. Kirkpatrick WR, Lopez-Ribot JL, McAtee RK, Patterson TF. Growth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions. J Clin Microbiol. 2000 Feb; 38(2):902-4.
    View in: PubMed
    Score: 0.040
  92. Monteagudo C, Lopez-Ribot JL, Murgui A, Casanova M, Chaffin WL, Martinez JP. Immunodetection of CD45 epitopes on the surface of Candida albicans cells in culture and infected human tissues. Am J Clin Pathol. 2000 Jan; 113(1):59-63.
    View in: PubMed
    Score: 0.040
  93. Sepulveda P, Lopez-Ribot JL, Gozalbo D, Cervera A, Martinez JP, Chaffin WL. Ubiquitin-like epitopes associated with Candida albicans cell surface receptors. Infect Immun. 1996 Oct; 64(10):4406-8.
    View in: PubMed
    Score: 0.032
  94. Sepulveda P, Cervera AM, Lopez-Ribot JL, Chaffin WL, Martinez JP, Gozalbo D. Cloning and characterization of a cDNA coding for Candida albicans polyubiquitin. J Med Vet Mycol. 1996 Sep-Oct; 34(5):315-22.
    View in: PubMed
    Score: 0.032
  95. Casanova M, Lopez-Ribot JL, Martinez JP, Sentandreu R. Characterization of cell wall proteins from yeast and mycelial cells of Candida albicans by labelling with biotin: comparison with other techniques. Infect Immun. 1992 Nov; 60(11):4898-906.
    View in: PubMed
    Score: 0.024
  96. Casanova M, Lopez-Ribot JL, Monteagudo C, Llombart-Bosch A, Sentandreu R, Martinez JP. Identification of a 58-kilodalton cell surface fibrinogen-binding mannoprotein from Candida albicans. Infect Immun. 1992 Oct; 60(10):4221-9.
    View in: PubMed
    Score: 0.024
  97. Martinez JP, Gil ML, Casanova M, Lopez-Ribot JL, Garcia De Lomas J, Sentandreu R. Wall mannoproteins in cells from colonial phenotypic variants of Candida albicans. J Gen Microbiol. 1990 Dec; 136(12):2421-32.
    View in: PubMed
    Score: 0.021
  98. Martinez JP, Lopez-Ribot JL, Gil ML, Sentandreu R, Ruiz-Herrera J. Inhibition of the dimorphic transition of Candida albicans by the ornithine decarboxylase inhibitor 1,4-diaminobutanone: alterations in the glycoprotein composition of the cell wall. J Gen Microbiol. 1990 Oct; 136(10):1937-43.
    View in: PubMed
    Score: 0.021
  99. S?nchez-Vargas LO, Ortiz-L?pez NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gait?n-Cepeda LA, Quind?s G. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol. 2005 Jun; 22(2):83-92.
    View in: PubMed
    Score: 0.015
  100. Redding SW, Bailey CW, Lopez-Ribot JL, Kirkpatrick WR, Fothergill AW, Rinaldi MG, Patterson TF. Candida dubliniensis in radiation-induced oropharyngeal candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun; 91(6):659-62.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support